Search Results
Jun 04, 2026, 06:00 ET Leading Vision Insurance Plans (2026): VSP Vision Care Ranked Leading Provider for Exams and Eyewear by Consumer365
exam, doctors measure visual acuity, update prescriptions, and evaluate the overall health of the eyes. Examinations may also help eye doctors detect l early signs of broader health conditions.1Plan structures allow benefits to be applied directly through participating providers. When
More news about: Consumer365.org
Jun 04, 2026, 05:08 ET 歐洲腎臟協會大會：FLOW 試驗指出，司美格魯肽可改善糖尿病及腎病患者的生活質素
這項新分析帶來以患者為核心的補充證據，顯示司美格魯肽的裨益不僅體現在傳統臨床指標上，更延伸至患者日常生活中的感受及機能表現。對於同時患有二型糖尿病 (T2D) 及慢性腎病 (CKD) 的患者，症狀、治療負擔以及身體機能減弱，都大大影響其日常安康，因此生活質素逐漸成為更重要的治療目標。FLOW 試驗共有 3,533 名隨機分配的參加者，其中 1,767 人接受司美格魯肽，1,766 人接受安慰劑。 研究採用 EQ-5D-5L 問卷來評估健康相關生活質素，亦即一種由患者自行填報的健康及福祉評量工具，涵蓋活動能力、自我照顧、日常活動、疼痛/不適、焦慮/抑鬱，以及整體健康觀感。經過兩年治療，健康效用得分（分數範圍從 0（死亡）到 1（完全健康））在司美格魯肽組維持平穩，而接受安慰劑的則有所下跌。 估算的治療差異為
More news about: ERA Congress
Jun 04, 2026, 04:39 ET ATFX Connect Partners in South Africa with the JSE to Bring JSE-Listed CFDs to Institutional Clients Across The Continent
traders"This partnership represents another major step in our African expansion strategy," said Dany Mawas, CEO of ATFX Africa & Co-founder of L7 Prime. "Working alongside the JSE and a couple of local South African banks allows us to deliver stronger, localised solutions to our partners and
More news about: ATFX Connect
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
application stage, rocbrutinib's dual covalent and non-covalent mechanism enables it to target C481-site and other resistance mutations such as T474I and L528W, providing a scientific basis for overcoming acquired resistance.The recommendation provides authoritative and standardized clinical guidance
More news about: Lupeng Pharmaceutical Ltd
Jun 04, 2026, 02:35 ET Emdoor Digital Showcases Full-Spectrum AI Devices at COMPUTEX 2026, Redefining Intelligent Experience Boundaries
assignable as VRAM, loading 70-billion-parameter models instantly. 154W performance output in a 2.69L body redefines portable productivity.FF26, Emdoor Digital's first Wildcat Lake mini PC, packs a 0.6L all-metal chassis, 65W output, 32 dB quiet operation, and quad 4K@120Hz displays. Two mATX motherboards
More news about: Emdoor Digital
Jun 03, 2026, 23:19 ET VARON unterstützt Kunden bei der Vorbereitung auf die Mobilität im Sommer mit Sonderrabatten auf Sauerstoffkonzentratoren
mobile Sauerstoffkonzentrator VL-2 wiegt 1,5 kg und liefert einen kontinuierlichen Sauerstofffluss von 3l/min. Er wurde für Benutzer entwickelt, die eine einfache, mobile Lösung für den täglichen Gebrauch suchen.Der
More news about: VARON
Jun 03, 2026, 21:26 ET Wiwynn and Shinwa Controls Announce Strategic Collaboration to Deliver Advanced Next-Generation Data Center Cooling Solutions
workload- and energy-optimized IT solutions from cloud to edge. Wiwynn's end-to-end capabilities span server design, system integration, and high-volume L10/L11 rack delivery, backed by a manufacturing network spanning Taiwan, the United States, Mexico, Malaysia, and the Czech Republic.For more information,
More news about: Wiwynn
Jun 03, 2026, 18:01 ET ERA 총회: FLOW 임상시험, 세마글루타이드가 당뇨병 및 신장 질환 환자의 삶의 질 개선과 관련 있음을 보여줘
무작위 배정된 참가자 3533명 중 1767명은 세마글루타이드를, 1766명은 위약을 투여받았다. 건강 관련 삶의 질은 이동성, 자기관리, 일상 활동, 통증/불편감, 불안/우울, 전반적인 건강 인식을 포함해 건강 상태와 웰빙을 평가하는 환자 보고 척도인 EQ-5D-5L 설문지를 통해 평가됐다.치료 2년 후 건강 효용 점수(0은 사망, 1은 완전한 건강 상태)는 세마글루타이드군에서 안정적으로 유지됐으나 위약군에서는 감소했다. 추정 치료 차이 +0.021(p=0.0001)은 연간 완전한 건강 상태로 지내는 날이 약 8일 추가되는
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
randomised participants in the FLOW trial, 1,767 received semaglutide and 1,766 received placebo. Health-related quality of life was assessed using the EQ-5D-5L questionnaire, a patient-reported measure of health status and well-being covering mobility, self-care, usual activities, pain/discomfort, anxiety/depression,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
randomised participants in the FLOW trial, 1,767 received semaglutide and 1,766 received placebo. Health-related quality of life was assessed using the EQ-5D-5L questionnaire, a patient-reported measure of health status and well-being covering mobility, self-care, usual activities, pain/discomfort, anxiety/depression,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA-Kongress: Die FLOW-Studie zeigt, dass Semaglutid die Lebensqualität bei Diabetes und Nierenerkrankungen verbessert
randomisierten Teilnehmern der FLOW-Studie erhielten 1.767 Semaglutid und 1.766 Placebo. Die gesundheitsbezogene Lebensqualität wurde anhand des EQ-5D-5L-Fragebogens bewertet, einem von den Patienten selbst erstellten Maß für den Gesundheitszustand und das Wohlbefinden, das Mobilität, Selbstversorgung,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutida ligada a melhor qualidade de vida em diabetes e doença renal, mostra teste DE FLUXO
no estudo FLOW, 1.767 receberam semaglutida e 1.766 receberam placebo. A qualidade de vida relacionada à saúde foi avaliada usando o questionário EQ-5D-5L, uma medida relatada pelo paciente do estado de saúde e bem-estar, abrangendo mobilidade, autocuidado, atividades habituais, dor/desconforto, ansiedade/depressão
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congrès de l'ERA : L'essai FLOW montre que le sémaglutide est associé à une meilleure qualité de vie dans le diabète et les maladies rénales
randomisés de l'étude FLOW, 1 767 ont reçu le semaglutide et 1 766 le placebo. La qualité de vie liée à la santé a été évaluée à l'aide du questionnaire EQ-5D-5L, une mesure de l'état de santé et du bien-être déclarée par le patient et portant sur la mobilité, les soins personnels, les activités habituelles,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: Semaglutida vinculada a una mejor calidad de vida en la diabetes y la enfermedad renal, muestra EL ENSAYO FLOW
ensayo FLOW, 1.767 recibieron semaglutida y 1.766 recibieron placebo. La calidad de vida relacionada con la salud se evaluó mediante el cuestionario EQ-5D-5L, una medida de estado de salud y bienestar informada por el paciente que cubre la movilidad, el autocuidado, las actividades habituales, el dolor/malestar,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: El ensayo FLOW muestra beneficios de la semaglutida
ensayo FLOW, 1.767 recibieron semaglutida y 1.766 recibieron placebo. La calidad de vida relacionada con la salud se evaluó mediante el cuestionario EQ-5D-5L, una medida autoinformada del estado de salud y el bienestar que abarca la movilidad, el autocuidado, las actividades cotidianas, el dolor/malestar,
More news about: ERA Congress
Jun 03, 2026, 17:13 ET Bitmine Immersion Technologies (BMNR) annuncia che le sue partecipazioni in ETH raggiungono i 5,42 milioni di token e che le partecipazioni totali in criptovalute e liquidità ammontano a 11,6 miliardi di dollari
totale pari a 446 milioni di dollari. Le partecipazioni in ETH di Bitmine rappresentano il 4,49% dell'offerta di ETH (pari a 120,7 milioni di ETH).L'11 maggio 2026, Bitmine ha pubblicato l'ultimo messaggio del suo presidente (
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Mündliche Präsentation auf der: ASCO-Jahrestagung;
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Présentation orale : Réunion annuelle de l'ASCO
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Ústna prezentácia na: ASCO Annual Meeting;
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Ústní prezentace na: ASCO Annual Meeting;
More news about: Amgen
Jun 03, 2026, 13:14 ET SNEC 2026: APsystems předvádí špičková úložiště energie pro komerční a průmyslové aplikace
APstorage 241L: Efektivní, spolehlivé a hospodárné úložiště pro komerční a průmyslový sektorAPstorage 241L přináší komerčním a průmyslovým zákazníkům vynikající nákladovou efektivitu, stabilní výkon a zvýšenou
More news about: APsystems
Jun 03, 2026, 13:12 ET SNEC 2026: APsystems predstavuje špičkové riešenia pre skladovanie energie pre komerčné a priemyselné aplikácie
APstorage 241L, ktorá poskytuje výkonnú a stabilnú dlhodobú prevádzku. APstorage 241L – efektívne,
More news about: APsystems
Jun 03, 2026, 13:09 ET SNEC 2026: APsystems prezentuje wiodące w branży rozwiązania magazynowania energii dla sektora C&I
APstorage 241L - wydajne, niezawodne i ekonomiczne rozwiązanie magazynowania energii dla sektora C&IAPstorage 241L został opracowany z myślą o wysokiej efektywności kosztowej, stabilnej pracy oraz podwyższonym
More news about: APsystems
Jun 03, 2026, 13:07 ET SNEC 2026: APsystems демонстрирует ведущие в отрасли решения для накопления и хранения энергии для коммерческих и промышленных объектов
APstorage 241L, обеспечивающий мощную и стабильную долгосрочную работу. APstorage 241L — эффективное,
More news about: APsystems
Jun 03, 2026, 13:04 ET APsystems presenta soluciones líderes en la industria para el almacenamiento de energía en el sector C&I
APstorage 241L: almacenamiento eficiente, fiable y rentable para el sector C&IEl APstorage 241L ofrece una economía superior, un rendimiento estable y una mayor seguridad para aplicaciones C&I.
More news about: APsystems